Lucius Partners Portfolio Company AerWave Medical, Inc. Updates its Progress in its First-in-Human Trial of its Ultrasound Based Lung Denervation System for Treatment of COPD and Asthma

News provided by

Aug 22, 2024, 08:00 ET

Study to confirm the safety and feasibility of the platform and to further confirm the shorter, less complex logistics of the Company's lung denervation procedures in Chronic Obstructive Pulmonary Disease and Asthma patients.

Extensive research on the role of nerves in the respiratory system suggests that lung denervation could offer an important option for patients and clinicians.

NEW YORK, Aug. 22, 2024 /PRNewswire/ -- Lucius Partners, LLC ("LP") today announced that its portfolio company, AerWave Medical, Inc., has completed treatment of its first three patients in its First-in-Human Trial (FIH) conducted at Healthycore in Tbilisi, Georgia. The trial's Primary Investigator is Univ. Prof. David Tchkonia, MD, PhD, Interventional Pulmonologist, Member of the European and World Associations for Bronchology and Interventional Pulmonology, Member of the Georgian Respiratory and Endoscopy Associations (GRA, GEA).

The study is evaluating the acute safety of patients undergoing lung denervation utilizing AerWave's novel approach to treat Asthma and Chronic Obstructive Pulmonary Disease (COPD). The study is expected to enroll five patients. The protocols are supported by extensive pre-clinical trials and data on both the safety and efficacy of dosimetry-based ultrasound denervation. The Company's technology holds promise for a more efficient, more efficacious, and safer clinical lung denervation procedure.

"We believe that AerWave's approach confers meaningful safety advantages over current treatments," said Reinhard Warnking, AerWave Medical's President and Chief Technology Officer. "As our proprietary ultrasound denervation approach is designed to be applied a safe distance from peri esophageal nerves to avoid dangerous esophageal side effects, reducing risks for patients and the interventional pulmonary community."

The efficiency and logistics of AerWave's first procedures are unparalleled as no ancillary devices like marker catheters, esophageal balloons or fluoroscopic monitoring are required.

"Ultrasound offers significant procedural and target flexibility as it provides nearly constant power distribution beyond the bronchial wall," stated Pat Gallagher, CEO. "Based on this adaptability, the team continues to pursue as additional pipeline opportunities lung tumor ablation and lung volume reduction (LVR). For example, in LVR the platform could shrink emphysematous tissue without implanting foreign materials through focal fibrotic resection, a potentially profound improvement in patient care."

Importantly, the system has, to date, demonstrated the utility of its 'one shot denervation' and its integrated diagnostic mode to ensure coupling.

"We are excited about the continued progress of the company's FIH trial," said James Ahern, Managing Partner at Laidlaw & Company and Founding Partner of Lucius Partners. "Our growing data sets suggest that the platform's unique capabilities could provide an important option for patients and clinicians. The team continues to explore new indications that will leverage our technology and create value for the healthcare system and our shareholders."

About AerWave Medical, Inc.
AerWave Medical is dedicated to creating and advancing medical devices to address unmet medical needs in Pulmonary medicine and beyond, using proprietary ultrasound technology developed by our highly accomplished scientists. For more information, please visit AerWave Medical.

About Lucius Partners, LLC
Lucius Partners is a consultancy that provides a broad suite of services to help healthcare companies grow, achieve milestones, and generate value for their shareholders. Learn more about Lucius Partners here.

Contact
Patrick Gallagher
Managing Partner, Lucius partners, LLC
[email protected]

SOURCE Lucius Partners, LLC